Article ; Online: Oral Anticoagulation in Patients with Chronic Liver Disease.
2023 Volume 59, Issue 2
Abstract: The administration of an anticoagulant in patients with liver disease (nonalcoholic steatohepatitis-NASH, nonalcoholic fatty liver disease-NAFLD, chronic hepatitis, or cirrhosis) who have an indication (atrial fibrillation, venous thrombosis, or ... ...
| Abstract | The administration of an anticoagulant in patients with liver disease (nonalcoholic steatohepatitis-NASH, nonalcoholic fatty liver disease-NAFLD, chronic hepatitis, or cirrhosis) who have an indication (atrial fibrillation, venous thrombosis, or pulmonary embolism) is challenging because there is an imbalance between thrombosis and bleeding. There is a need to focus our attention on preventing risk factors because diabetes, obesity, dyslipidemia, smoking, and sedentary behavior are risk factors for both NASH/NAFLD and AF, and these patients require anticoagulant treatment. Patients with advanced liver disease (Child-Pugh C) were excluded from studies, so vitamin K antagonists (VKAs) are still recommended. Currently, VKAs are recommended for other conditions (antiphospholipid syndrome, mitral valve stenosis, and mechanical valve prosthesis). Amongst the patients under chronic anticoagulant treatment, especially for the elderly, bleeding as a result of the improper use of warfarin is one of the important causes of emergency admissions due to adverse reactions. DOACs are considered to be efficient and safe, with apixaban offering superior protection against stroke and a good safety profile as far as major bleeding is concerned compared to warfarin. DOACs are safe in the Child-Pugh A and B classes (except rivaroxaban), and in the Child-Pugh C class are contraindicated. Given that there are certain and reliable data for chronic kidney disease regarding the recommendations, in liver function impairment more randomized studies must be carried out, as the current data are still uncertain. In particular, DOACs have a simple administration, minimal medication interactions, a high safety and effectiveness profile, and now a reversal agent is available (for dabigatran and idarucizumab). Patients are also statistically more compliant and do not require INR monitoring. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Humans ; Aged ; Warfarin/therapeutic use ; Non-alcoholic Fatty Liver Disease/complications ; Anticoagulants/therapeutic use ; Rivaroxaban/adverse effects ; Stroke/prevention & control ; Atrial Fibrillation/complications ; Hemorrhage/chemically induced | |||||
| Chemical Substances | Warfarin (5Q7ZVV76EI) ; Anticoagulants ; Rivaroxaban (9NDF7JZ4M3) | |||||
| Language | English | |||||
| Publishing date | 2023-02-12 | |||||
| Publishing country | Switzerland | |||||
| Document type | Journal Article ; Review | |||||
| ZDB-ID | 2188113-3 | |||||
| ISSN | 1648-9144 ; 1010-660X | |||||
| ISSN (online) | 1648-9144 | |||||
| ISSN | 1010-660X | |||||
| DOI | 10.3390/medicina59020346 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6270: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.